Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

This is an open-label, multi-center study. The total duration of study will be approximately
17 weeks per participant, including Screening phase (up to 4 weeks prior to first probe
cocktail administration). Participants will have 4 in-patient periods on Day 1, 8, 15 and 36
(3 periods consisting of 3 days and 2 nights each and 1 consisting of 2 days and 1 night)
followed by follow up period (up to Day 92). All Participants will receive a single 200 mg
subcutaneous (SC) injection (2*100 mg) of guselkumab on Day 8 and probe cocktail on Days 1,
15 and 36. Blood samples will be collected for the evaluation of pharmacokinetics and
immunogenicity at pre-dose and post-dose of study treatment. Participants' safety will be
monitored throughout the study.

Inclusion Criteria:

- Have a diagnosis of plaque-type psoriasis with or without psoriatic arthritis (PsA)
for at least 6 months before Day 1

- Have a Psoriasis Area and Severity Index (PASI) greater than or equal to (>=) 12 at
Screening

- Have an Investigator's Global Assessment (IGA) >= 3 at Screening

- Have an involved body surface area (BSA) >= 10 percent (%) at Screening

- Be a candidate for phototherapy or systemic treatment for psoriasis

Exclusion Criteria:

- Has a history of or current signs or symptoms of severe, progressive, or uncontrolled
renal, hepatic, cardiac (including unstable cardiovascular disease, defined as a
recent clinical deterioration (example, unstable angina, rapid atrial fibrillation) in
the last 3 months or a cardiac hospitalization within the last 3 months), vascular,
pulmonary, gastrointestinal, endocrine, neurologic, hematologic, bleeding disorder,
rheumatologic, psychiatric, or metabolic disturbances

- Have a pulse oximetry value less than (<) 94 % at Screening

- Genetically determined poor metabolizers of CYP2C9, CYP2C19, and CYP2D6 substrates

- Is currently undergoing or has previously undergone allergy immunotherapy for a
history of anaphylactic reactions

- Has a transplanted organ (with exception of a corneal transplant greater than (>) 3
months before Day 1)